PuraPharm Completes Key Share Transactions to Enhance Market Position
I'm PortAI, I can summarize articles.
PuraPharm Corp. Ltd. (HK:1498) has completed a Patent Licence Agreement and a Subscription Agreement, issuing 93,488,372 and 46,512,000 new shares respectively. These transactions significantly enhance the company's share capital and are expected to impact its financial structure and market position. The latest analyst rating for PuraPharm stock is a Hold with a price target of HK$0.50. The company, based in the Cayman Islands, specializes in herbal medicines and health products, with a current market cap of HK$163.9M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments